APUS vs EIX
Apimeds Pharmaceuticals US, Inc. (APUS) versus Edison International (EIX) — a side-by-side from cached financials, not a winner call.
Apimeds Pharmaceuticals US, Inc. (APUS) is a drug manufacturers - specialty & generic company listed on US.
Edison International (EIX) is a utilities - regulated electric company listed on US.
APUS does not have a complete income-statement cache yet.
Latest reported EIX revenue for 2024-12-31 was $17.60B. Net income was $1.55B. Revenue was up 7.7% from 2023-12-31 to 2024-12-31. EIX currently screens at market cap $19.73B and trailing P/E 7.3.
APUS currently screens at market cap $2.4M. EIX currently screens at market cap $19.73B and trailing P/E 7.3.
Not investment advice. Open the APUS and EIX stock pages for the full models.
Not investment advice.